ライフサイエンスコーパス: prednisolone

1 3 months followed by azathioprine plus oral prednisolone).

2 eir response to 2 weeks of therapy with oral prednisolone.

3 with basiliximab, mycophenolate mofetil, and prednisolone.

4 cerbations but not the number requiring oral prednisolone.

5 ccurred in 4 patients and were attenuated by prednisolone.

6 en including cyclosporine, azathioprine, and prednisolone.

7 hylprednisolone for 3 days, followed by oral prednisolone.

8 acetate for 3 days followed by 1 mg/kg oral prednisolone.

9 detected at 96 hpf in response to 1 mug/L of prednisolone.

10 1:1 ratio) to receive either indomethacin or prednisolone.

11 azol, methylprednisolone, triamcinolone, and prednisolone.

12 l lines showed an increase in sensitivity to prednisolone.

13 ely associated with the clinical response to prednisolone.

14 d resensitizes B-cell precursor ALL cells to prednisolone.

15 e allograft, when compared with conventional prednisolone.

16 rum levels predicted MOF and the response to prednisolone.

17 reater extents than did alpha-tocopherol and prednisolone.

18 onic models of inflammation is equivalent to prednisolone.

19 80%) of 64 patients who received 6 months of prednisolone.

20 ere significantly changed by 14 days of oral prednisolone.

21 Responders were continued with prednisolone.

22 on to abiraterone acetate plus prednisone or prednisolone.

23 igher-dose (n = 2) cohorts were treated with prednisolone.

24 the immunosuppressive effects observed with prednisolone.

25 f environmentally relevant concentrations of prednisolone (0.1, 1, and 10 mug/L) during zebrafish emb

26 assigned to doxycycline (200 mg per day) or prednisolone (0.5 mg/kg per day) using random permuted b

27 nous methyl prednisolone followed by/or oral prednisolone 1 mg/kg daily with slow taper plus IMT with

28 a ratio of 1:1:1 as follows: ketorolac 0.5%, prednisolone 1%, or saline tears.

29 All received a course of tapering oral prednisolone (1 mg/kg prior to taper).

30 uired rescue intervention with icatibant and prednisolone; 1 patient required tracheotomy.

31 el (75 mg/m(2)) for six 3-weekly cycles with prednisolone 10 mg daily.

32 Minimum doses were prednisolone 10 mg four times a day or intramuscular tet

33 and mesalazine (1000 mg t.i.d.) was added to prednisolone (10.0 mg/d).

34 se] intravenously on day 1 of the cycle, and prednisolone 100 mg orally once daily on days 1-5).

35 to the widely used synthetic glucocorticoid prednisolone 2 in vivo.

36 rednisolone (4 mg/kg/d for 2 weeks) and oral prednisolone (2 mg/kg/d for 2 weeks) followed by a taper

37 limus (10 ng/mL), everolimus (10 ng/mL), and prednisolone (200 ng/mL).

38 chiolitis, and immediately administered oral prednisolone (30 mg daily).

39 Among 525 patients (48.7%) who received oral prednisolone, 320 (61%) required a dose of more than 40

40 and rituximab 375 mg/m(2) on day 1, and oral prednisolone 40 mg/m(2) on days 1-5, administered every

41 l to evaluate the efficacy of treatment with prednisolone (40 mg daily) or pentoxifylline (400 mg 3 t

42 e 1000 mg once daily plus oral prednisone or prednisolone 5 mg twice daily during and after radium-22

43 plus abiraterone acetate (1000 mg daily) and prednisolone (5 mg daily) (combination therapy).

44 ocetaxel (75 mg/m(2) intravenous, day 1) and prednisolone (5 mg twice daily, oral, day 1-21) and were

45 l standard therapy consisting of intravenous prednisolone (500 mg) plus clemastine (2 mg).

46 ctorial design led to 547 patients receiving prednisolone; 546 were treated with pentoxifylline.

47 n after treatment than of patients not given prednisolone (6%) (OR, 1.70; 95% CI, 1.07-2.69; P = .024

48 regimens consisted of postoperative topical prednisolone acetate (PA) alone or with a nonsteroidal a

49 omized to ketorolac 4 times a day (qid) + 1% prednisolone acetate (PA) every hour while awake (q1hWA,

50 coids, beclomethasone dipropionate (BDP) and prednisolone acetate (PDNA), on force production in isol

51 Participants concurrently used topical prednisolone acetate 1% 4x daily for 3 months, 3x daily

52 ed IOP post DALK included the use of topical prednisolone acetate 1% compared with dexamethasone 0.1%

53 51, 95% CI = 1.43-147.23) and use of topical prednisolone acetate 1% compared with dexamethasone 0.1%

54 e daily and less than or equal to 2 drops of prednisolone acetate 1%, and no treatment failure due to

55 mized to receive placebo (artificial tears), prednisolone acetate 1%, or ketorolac tromethamine 0.5%

56 reement was less than 15% for 4 medications (prednisolone acetate [generic], betaxolol HCl [Betoptic;

57 Prednisolone acetate eye drops 1% 5 times daily for the

58 After an internal change of therapy regimen: Prednisolone acetate eye drops 1% hourly for the first p

59 ents were randomized to 0.1% nepafenac or 1% prednisolone acetate eye drops in both eyes.

60 A single GC IDI (25 mg prednisolone acetate) during discography (n = 67) or dis

61 the results have been controversial, and how prednisolone affects liver disease progression remains u

62 older patients using medium to high doses of prednisolone, alendronate treatment was associated with

63 Mice were treated with prednisolone, alendronate, and both in combination for u

64 Prednisolone alone and in combination with alendronate e

65 ntoxifylline and prednisolone, compared with prednisolone alone, did not result in improved 6-month s

66 Prednisolone, alone or in some cases in combination with

67 In addition, administration of prednisolone also enhanced acetaminophen-, ethanol-, or

68 Treating mice with prednisolone also suppressed inflammatory responses in a

69 ks compared with 92 (91%) of 101 patients on prednisolone, an adjusted difference of 18.6% (90% CI 11

70 ctions (24 hpf) was significantly reduced by prednisolone and 0.1 mug/L increased the distance embryo

71 77%) of 62 patients who received 3 months of prednisolone and 51 (80%) of 64 patients who received 6

72 olone-matched placebo, a group that received prednisolone and a pentoxifylline-matched placebo, a gro

73 Herein, we evaluated prednisolone and alendronate for their therapeutic poten

74 Combined treatment of prednisolone and alendronate provided best improvement i

75 As the disease was successfully treated with prednisolone and budesonide, the model will be helpful t

76 enal function was significantly lower in the prednisolone and chlorambucil group than in the supporti

77 t in all three groups but were higher in the prednisolone and chlorambucil group than in the supporti

78 etory renal function, 6 months' therapy with prednisolone and chlorambucil is the treatment approach

79 y assigned 108 patients, 33 of whom received prednisolone and chlorambucil, 37 ciclosporin, and 38 su

80 ensu stricto was dramatically reduced in the prednisolone and combined IS drug groups.

81 Despite prednisolone and cortisol levels commonly being used as

82 uM curcumin, +/-5 mg/L theophylline, +/-1uM prednisolone and cytokines, and SIRT1 assessed using flo

83 Oral prednisolone and indomethacin had similar analgesic effe

84 We hypothesized that prednisolone and infliximab exert different effects on l

85 explaining the distinct metabolic effects of prednisolone and infliximab.

86 Both prednisolone and M. indicus pranii, each as compared wit

87 times a day (n=133) for 28 days, or 40 mg of prednisolone and matching placebo (n=137) for 28 days.

88 Surprisingly and in contrast to prednisolone and MPA, neither tacrolimus nor everolimus

89 Prednisolone and pentoxifylline are both recommended for

90 tched placebo, or a group that received both prednisolone and pentoxifylline.

91 e detection of boldenone, or its conjugates, prednisolone and prednisone.

92 with abiraterone acetate plus prednisone or prednisolone and radium-223 in such patients.

93 In vitro, prednisolone and the pharmacologic GR antagonist mifepri

94 rimary outcome between patients who received prednisolone and those who received placebo (23.8% and 2

95 utcomes of patients treated with and without prednisolone, and identified risk factors for developmen

96 cantly suppressed by tacrolimus, everolimus, prednisolone, and MPA (P<0.05).

97 onse was affected by tacrolimus, everolimus, prednisolone, and mycophenolic acid (MPA) in clinically

98 e preferentially inhibited by tacrolimus and prednisolone, and not by everolimus.

99 uding plasmapheresis, immunosuppression with prednisolone, and numerous transfusions.

100 tients treated with docetaxel, prednisone or prednisolone, and placebo in the VENICE trial, and 470 p

101 trol; (2) 5 mg/kg/day LANZO; (3) 5 mg/kg/day prednisolone; and (4) combined treatment of 5 mg/kg/day

102 th groups received equal cumulative doses of prednisolone (approximately 3360 mg/m(2)).

103 Patients with SAH given prednisolone are at greater risk for developing serious

104 gistic activity with pitavastatin identified prednisolone as the most prominent hit.

105 (cyclophosphamide, doxorubicin, vincristine, prednisolone)-based chemotherapy were prospectively foll

106 ckdown increased sensitivity specifically to prednisolone by increasing the levels of the glucocortic

107 nfluorinated glucocorticoids, prednisone and prednisolone, can be used throughout pregnancy, although

108 Prednisolone cannot be routinely recommended for all you

109 Oral prednisolone caused a similar degree of suppression of e

110 Oral prednisolone changes the transcriptomic profile of the A

111 lophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) every 2 weeks improves outcomes in p

112 lophosphamide, doxorubicin, vincristine, and prednisolone (CHOP)-based chemotherapy confers improved

113 nvestigated before and after 2 weeks of oral prednisolone (Clintrials.gov NCT00331058 and NCT00327197

114 is, 4-week treatment with pentoxifylline and prednisolone, compared with prednisolone alone, did not

115 G(2)(0)(0)(0) conjugates reduced the maximum prednisolone concentration in the perfusate (Cmax) by 3.

116 making interpretation of findings and serum prednisolone concentrations difficult.

117 With the exception of PEG(3)(4)(0)(0)-prednisolone, conjugates did not induce a significant la

118 s, which is an mTOR inhibitor (P/EVL; n=10), prednisolone/CsA (P/CsA; n=7), or prednisolone/MPS (P/MP

119 ied renal transplant recipients treated with prednisolone, cyclosporine A (CsA), and mycophenolate so

120 A dose of 12.5-25.0 mg prednisolone daily or equivalent leads to rapid improvem

121 subjects and patients with mild, severe, and prednisolone-dependent asthma under stable conditions an

122 nts with severe asthma, and 30 patients with prednisolone-dependent asthma) parameters of inflammatio

123 igher proportion (10%) of patients receiving prednisolone developed an infection after treatment than

124 23 to abiraterone acetate plus prednisone or prednisolone did not improve symptomatic skeletal event-

125 Prednisolone disrupted fecal microbiota community struct

126 The average oral prednisolone dose at baseline was 16.4+/-1.7 mg/day, and

127 The prednisolone dose was reduced to 7.5 mg/d.

128 g symptoms under maintenance therapy of 5 mg prednisolone during the 3-year follow up.

129 glucocorticoid use, those with <5.0 mg daily prednisolone-equivalent dose had increased all-cause CVD

130 4% in periods of non-use to 8.9% for a daily prednisolone-equivalent dose of >=25.0 mg.

131 -variant daily and cumulative glucocorticoid prednisolone-equivalent dose-related risks and hazard ra

132 ng </=5 mg (n = 64) and >5 mg (n = 53) daily prednisolone-equivalent doses.

133 ion followed by double therapy consisting of prednisolone/everolimus, which is an mTOR inhibitor (P/E

134 lophosphamide, doxorubicin, vincristine, and prednisolone every 21 days (R-CHOP21) relapse or develop

135 to 23 months were randomized to receive oral prednisolone (first dose of 2 mg/kg, followed by 2 mg/kg

136 ith nephrotic syndrome to either 3 months of prednisolone followed by 3 months of placebo (n=74) or 6

137 zed clinical protocol was intravenous methyl prednisolone followed by/or oral prednisolone 1 mg/kg da

138 ily or intermittent (10 days on/10 days off) prednisolone for a mean duration of treatment of 4 years

139 non-inferior to standard treatment with oral prednisolone for short-term blister control in bullous p

140 hils during the clinical course and received prednisolone for the same, which resulted in the resolut

141 randomly assigned to doxycycline and 121 to prednisolone from 54 UK and seven German dermatology cen

142 more minor adverse events than those in the prednisolone group (19% vs. 6%; P < 0.001).

143 Mean symptom severity was 1.99 points in the prednisolone group and 2.16 points in the placebo group

144 (interquartile range [IQR], 3-8 days) in the prednisolone group and 5 days (IQR, 3-10 days) in the pl

145 from baseline to 2 weeks was observed in the prednisolone group compared with the nepafenac group (+2

146 For short-term outcomes, the prednisolone group had less cough, rhinitis, noisy breat

147 (1) conventional immunomodulators (ie, oral prednisolone >10 mg/day, thiopurines, methotrexate); (2)

148 Prednisolone improved muscle pathology with significant

149 Liposomal delivery of prednisolone improved renal bio-availability, increased

150 Abiraterone acetate plus prednisone or prednisolone improves progression-free survival and over

151 Abiraterone acetate plus prednisolone improves survival in men with relapsed pros

152 BMS-986126 also demonstrated synergy with prednisolone in assays of TLR7- and TLR9-induced IFN tar

153 o the renal benefits observed with high-dose prednisolone in control mice.

154 Nepafenac was noninferior to prednisolone in controlling inflammation after LPI in PA

155 The use of systemic prednisolone in eyes with vasculitis was associated with

156 HDAC inhibitor SAHA restores sensitivity to prednisolone in TBL1XR1-depleted cells.

157 s/mL (most sensitive cutoff) benefitted from prednisolone in terms of less risk of physician-confirme

158 in score were observed with indomethacin and prednisolone in the ED (approximately 10 mm [rest] and 2

159 nd 41 mg/kg) of naproxcinod and 0.9 mg/kg of prednisolone in their food for 9 months.

160 mortality in patients with SAH treated with prednisolone, independent of model for end-stage liver d

161 Glycine treatment augmented the prednisolone-induced reduction in fibrosis in diaphragm

162 ymptoms and increases circulating IGF-I, but prednisolone induces catabolism, whereas infliximab may

163 In patients who did not receive prednisolone, infection was not independently associated

164 previously taken alendronate at the time of prednisolone initiation.

165 Prednisolone is a commonly prescribed synthetic glucocor

166 Prednisolone is a corticosteroid that has been used to t

167 Prednisolone is a safe, effective first-line option for

168 Prednisolone is advocated for treatment of SAH, but can

169 onate treatment in older patients using oral prednisolone is associated with decreased hip fracture r

170 le is forbidden in the European Union, while prednisolone is permitted for therapeutic purposes.

171 However, relapses are common when prednisolone is tapered.

172 1-2.7 years in comparison with prednisone or prednisolone (log-rank p<0.012).

173 o investigate whether liposomal-encapsulated prednisolone (LP) facilitates local exposure to enhance

174 100% of these patients achieving "success" (prednisolone </=10 mg and sustained control) with the ne

175 s with respect to the eventual initiation of prednisolone maintenance and/or other immunosuppressive

176 eived a pentoxifylline-matched placebo and a prednisolone-matched placebo, a group that received pred

177 , a group that received pentoxifylline and a prednisolone-matched placebo, or a group that received b

178 may become prednisolone sensitive indicating prednisolone may be an effective adjuvant therapy in som

179 Prednisolone may lead to a prompt amelioration of eosino

180 diagnosed with PG and treated with high-dose prednisolone, methotrexate and cyclosporine.

181 roid cortivazol, other particulate steroids (prednisolone, methylprednisolone, and triamcinolone) cau

182 Results With prednisolone, methylprednisolone, or triamcinolone, bloo

183 Prednisolone might be beneficial in a subgroup of childr

184 starting doxycycline and 36% (41 of 113) for prednisolone (mITT), an adjusted difference of 19.0% (95

185 mpared with those treated with melphalan and prednisolone (MP) (16.0% [n = 68 of 425] vs 4.1% [n = 17

186 VL; n=10), prednisolone/CsA (P/CsA; n=7), or prednisolone/MPS (P/MPS; n=9).

187 Mice were treated for 14 days with prednisolone, mycophenolate mofetil, tacrolimus, a combi

188 dney transplantation in recipients receiving prednisolone, mycophenolate, and tacrolimus.

189 patients with active IBD treated with either prednisolone (n = 17) or infliximab (n = 21) were examin

190 lone (n = 547) and patients not treated with prednisolone (n = 545) using logistic regression.

191 valuated separately in patients treated with prednisolone (n = 547) and patients not treated with pre

192 were taken before and after 14 days of oral prednisolone (n = 6) or placebo (n = 6).

193 by 3 months of placebo (n=74) or 6 months of prednisolone (n=76), and median follow-up was 47 months.

194 ients with tuberculous pericarditis, neither prednisolone nor M. indicus pranii had a significant eff

195 were more frequent in patients treated with prednisolone (odds ratio [OR], 1.27; 95% confidence inte

196 to receive either a combination of 40 mg of prednisolone once a day and 400 mg of pentoxifylline 3 t

197 f illegal administration of dexamethasone or prednisolone or 17beta-estradiol on Charolais bulls.

198 The AIH could be treated with prednisolone or adoptive transfer of polyspecific Tregs.

199 ith a reduction of systemic corticosteroids (prednisolone or equivalent) to a dose of <10 mg/day at w

200 ll decreased following treatment with either prednisolone or infliximab (all p < 0.05).

201 Anti-inflammatory treatment with prednisolone or infliximab ameliorates symptoms and incr

202 h disease remission following treatment with prednisolone or infliximab.

203 Prednisolone or pentoxifylline is recommended for severe

204 ign to evaluate the effect of treatment with prednisolone or pentoxifylline.

205 probable tuberculous pericarditis to either prednisolone or placebo for 6 weeks and to either M. ind

206 subcutaneous insertion of long-term release prednisolone or placebo pellets.

207 or at least 4 weeks and were taking a stable prednisolone or prednisone dose to receive 300 mg of mep

208 placebo group, had an average daily dose of prednisolone or prednisone of 4.0 mg or less per day dur

209 tion (1:1) of type of hormonal therapy used (prednisolone or tetracosactide depot).

210 up were from the second day given 37.5 mg of prednisolone oral tablet daily (for a maximum of up to 4

211 y 60% (P < 0.01) in dko mice co-treated with prednisolone over an 8 week treatment period.

212 on of clinical scores was observed with oral prednisolone (P < 0.0001) but not for the CCR4 inhibitor

213 iated TEC lysis was efficiently inhibited by prednisolone (P<0.05).

214 cyclosporine A and received either 10 mg/kg prednisolone (P), or LP intravenously on day 0, 3, and 6

215 olone versus 7% of those who did not receive prednisolone (P=0.002).

216 Whilst administration of long-term release prednisolone pellets provided a robust GIO animal model

217 o group, and 13% (35 of 260 patients) in the prednisolone-pentoxifylline group.

218 long-circulating liposomes (LCL) containing prednisolone phosphate (PLP-LCL) in a mouse model of art

219 group (n = 49) or the steroid group (topical prednisolone phosphate; n = 57); both regimens were tape

220 acebo group, 14% (38 of 266 patients) in the prednisolone-placebo group, 19% (50 of 258 patients) in

221 mal treatment for patients with severe AH is prednisolone, possibly in combination with N-acetyl cyst

222 Prednisolone potentiated the activity of pitavastatin in

223 e; and (4) combined treatment of 5 mg/kg/day prednisolone (PRED) and 5 mg/kg/day LANZO.

224 ayers were treated with dexamethasone (DEX), prednisolone (PRED), or GW870086X for 5 days and then as

225 psing/refractory EGPA receiving stable OGCs (prednisolone/prednisone, >=7.5-50 mg/d) for 4 or more we

226 a, but not treatment with the glucocorticoid prednisolone, prevented these changes.

227 lophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) to uncover molecular subgroups lin

228 lophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP; rituximab 375 mg/m(2), cyclophosph

229 citabine, cyclophosphamide, vincristine, and prednisolone (R-GCVP) in patients considered unfit for a

230 Glucocorticoids (e.g. prednisolone) remain the only drugs with a favorable imp

231 otein kinase (MAPK) pathway as a mediator of prednisolone resistance in pediatric ALL.

232 cently implicated in B-ALL proliferation and prednisolone resistance, and the novel target CTNND1, en

233 cursor ALL cells and induces stroma-mediated prednisolone resistance.

234 er for methylprednisolone, triamcinolone, or prednisolone, respectively, vs 21.0, 21.4, and 19.1 capi

235 Treatment with prednisolone resulted in an immediate response with rapi

236 Dck-defective leukemic cells may become prednisolone sensitive indicating prednisolone may be an

237 nes were established with one clone becoming prednisolone sensitive.

238 hairpin RNA screen to identify mediators of prednisolone sensitivity in ALL cell lines.

239 glucocorticoid resistance, we determined the prednisolone sensitivity of primary leukemia cells from

240 This multicenter trial compared 1.0% prednisolone sodium phosphate to placebo in the treatmen

241 nation of suboptimal doses of BMS-986126 and prednisolone, suggesting the potential for steroid spari

242 Two 20-mg prednisolone tablets (n = 199) or matched placebo (n = 2

243 The control group received 37.5 mg of prednisolone tablets daily from the second day for 4 day

244 Prednisolone, tacrolimus, and mycophenolate mofetil modi

245 he patients received 0.5 to 1 mg/kg/day oral prednisolone that was tapered over 4 to 6 weeks.

246 classified colitis n = 11) that were on oral prednisolone therapy about to be discontinued.

247 He responded to 4-week period of induction prednisolone therapy and had no recurring symptoms under

248 There was no association between prednisolone therapy and infection during treatment (OR,

249 Oral prednisolone therapy significantly reduced the median nu

250 Prednisolone therapy, as compared with placebo, was asso

251 ed infection that developed within 7 days of prednisolone therapy, independent of Model for End-Stage

252 nd mDC shows a differential response to oral prednisolone therapy.

253 Environmentally relevant concentrations of prednisolone therefore alter early zebrafish ontogeny an

254 patients at high risk of infection if given prednisolone; these data could be used to select therapi

255 mbers MEK2 and MEK4 increased sensitivity to prednisolone through distinct mechanisms.

256 t reduction in the lowest daily dose of oral prednisolone throughout the entire treatment course afte

257 nd glucocorticoids (GCs) (ie, dexamethasone, prednisolone) to trigger apoptosis in ALL cells.

258 phy revealed that contrary to C57BL/6J mice, prednisolone treated CD1 mice developed osteoporosis.

259 of 1+ anterior chamber cell at 2 weeks and 4 prednisolone-treated eyes (5.4%) failing to meet the pri

260 levation from baseline (P = 0.10), whereas 2 prednisolone-treated eyes and no nepafenac-treated eyes

261 s after LPI, 3 nepafenac-treated eyes and 10 prednisolone-treated eyes demonstrated a 6- to 15-mmHg I

262 Four weeks after LPI, more prednisolone-treated eyes showed IOP elevation of 6 to 1

263 alendronate after at least 3 months of oral prednisolone treatment (>/=5 mg/d) were identified.

264 os hatched significantly increased following prednisolone treatment (1 and 10 mug/L), while growth an

265 ctive adjuvant for improving the efficacy of prednisolone treatment and improving the quality of life

266 Prolonged prednisolone treatment for the initial episode of childh

267 verse effects, we have studied the effect of prednisolone treatment in dystrophin/utrophin double kno

268 d flow cytometric analyses demonstrated that prednisolone treatment inhibited hepatic macrophage and

269 to study the short- and long-term effects of prednisolone treatment of the first acute, moderate-to-s

270 Prednisolone treatment prevents T/NKT cell hepatitis but

271 is related to upregulation of mTOR, and that prednisolone treatment reduces the expression of mTOR an

272 However, prednisolone treatment was unable to improve the myogene

273 Following seven days of prednisolone treatment, total and bioactive IGF-I were i

274 ce showed no differences between placebo and prednisolone treatment.

275 er a median of 5 days (range, 2 to 35) after prednisolone treatment.

276 dition, the long-term detrimental effects of prednisolone typically seen in mdx skeletal and heart fu

277 erence of 18.6% (90% CI 11.1-26.1) favouring prednisolone (upper limit of 90% CI, 26.1%, within the p

278 difference between the groups in the risk of prednisolone use for exacerbation was found (hazard rati

279 occurred in 13% of the patients treated with prednisolone versus 7% of those who did not receive pred

280 l [CI], 0.77 to 1.49; P=0.69), and that with prednisolone was 0.72 (95% CI, 0.52 to 1.01; P=0.06).

281 Prednisolone was associated with a reduction in 28-day m

282 ic prostate cancer, ADT plus abiraterone and prednisolone was associated with significantly higher ra

283 On days when the eosinophil count was lower, prednisolone was not administered.

284 At the time of flare up, administration of prednisolone was remarkably effective.

285 Therefore, immunosuppressive treatment with prednisolone was started.

286 Interestingly, prednisolone was the most powerful inhibitor of NK cell

287 Prednisolone was therefore seen to be effective for trea

288 ly proven SAH, nonresponsive to 40 mg/day of prednisolone were randomized to G-CSF (12 doses, 300 mug

289 of cyclosporine, mycophenolate mofetil, and prednisolone were well tolerated and equally effective i

290 articularly in the presence of moderate-dose prednisolone, where peak plasma glucose occurs 7 to 8 hr

291 ions after treatment than patients not given prednisolone, which may offset its therapeutic benefit.

292 t contraction was differentially affected by prednisolone while heart rate and oxygen consumption bot

293 ive cases, oral NSAIDs were replaced by oral prednisolone with cyclosporine, azathioprine, or mycophe

294 logues, fluorouracil, azathioprine, and oral prednisolone with improved outcomes for vitiligo.

295 Measurement of blood prednisolone with or without cortisol was used in eight

296 which was at least as effective as high-dose prednisolone with potentially fewer adverse effects.

297 Nepafenac was noninferior to prednisolone with regard to inflammation control, with 1

298 ut alendronate use from 6076 patients taking prednisolone with the same dose and treatment time crite

299 ommend combined therapy with albendazole and prednisolone, with consideration for increased steroid d

300 tenuated disease as effectively as high-dose prednisolone without the systemic immunosuppressive effe